Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition by Cervera-Carrascon, Victor et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20
OncoImmunology
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/koni20
Tumor microenvironment remodeling by an
engineered oncolytic adenovirus results in
improved outcome from PD-L1 inhibition
Victor Cervera-Carrascon , Dafne C.A. Quixabeira , Joao Manuel Santos ,
Riikka Havunen , Sadia Zafar , Otto Hemminki , Camilla Heiniö , Eleonora
Munaro , Mikko Siurala , Suvi Sorsa , Tuomas Mirtti , Petrus Järvinen ,
Markus Mildh , Harry Nisen , Antti Rannikko , Marjukka Anttila , Anna
Kanerva & Akseli Hemminki
To cite this article: Victor Cervera-Carrascon , Dafne C.A. Quixabeira , Joao Manuel Santos ,
Riikka Havunen , Sadia Zafar , Otto Hemminki , Camilla Heiniö , Eleonora Munaro , Mikko Siurala ,
Suvi Sorsa , Tuomas Mirtti , Petrus Järvinen , Markus Mildh , Harry Nisen , Antti Rannikko ,
Marjukka Anttila , Anna Kanerva & Akseli Hemminki (2020) Tumor microenvironment remodeling
by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition,
OncoImmunology, 9:1, 1761229, DOI: 10.1080/2162402X.2020.1761229
To link to this article:  https://doi.org/10.1080/2162402X.2020.1761229
© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC.
View supplementary material 
Published online: 22 May 2020. Submit your article to this journal 
Article views: 395 View related articles 
View Crossmark data
ORIGINAL RESEARCH
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results 
in improved outcome from PD-L1 inhibition
Victor Cervera-Carrascon a,b, Dafne C.A. Quixabeiraa, Joao Manuel Santosa,b, Riikka Havunena,b, Sadia Zafara, 
Otto Hemminkia,c, Camilla Heiniöa, Eleonora Munaroa, Mikko Siuralaa,b, Suvi Sorsaa,b, Tuomas Mirtti d,e,f, 
Petrus Järvinen c, Markus Mildhc, Harry Nisenc, Antti Rannikko c, Marjukka Anttilag, Anna Kanervaa,h, 
and Akseli Hemminkia,b,i
aCancer Gene Therapy Group, Translational Immunology Research Program and Department of Oncology, University of Helsinki, Helsinki, Finland; 
bTILT Biotherapeutics Ltd, Helsinki, Finland; cDepartment of Urology, Helsinki University Hospital, Helsinki, Finland; dInstitute for Molecular Medicine 
Finland (FIMM), University of Helsinki, Helsinki, Finland; eDepartment of Pathology, Medicum, University of Helsinki, Helsinki, Finland; fDepartment of 
Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland; gPathology Unit, Finnish Food Safety Authority (EVIRA), Helsinki, Finland; 
hDepartment of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland; iHelsinki University Hospital Comprehensive Cancer 
Center, Helsinki, Finland
ABSTRACT
Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. 
Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adeno-
viruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to assess if they 
increase the response rate to checkpoint inhibition, as these features have been regarded as predictive for 
the responses. When Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (an oncolytic adenovirus coding for TNFa and IL-2, 
also known as TILT-123) and checkpoint inhibitors were used together in fresh urological tumor histo-
cultures, a significant shift toward immune activity (not only tumor necrosis alpha and interleukin-2 but 
also interferon gamma and granzyme B) and increased T-cell trafficking signals (CXCL10) was observed. In 
vivo, our viruses enabled an anti-PD-L1 (a checkpoint inhibitor) delivering complete responses in all the 
treated animals (hazard ratios versus anti-PD-L1 alone 0.057 [0.007; 0.451] or virotherapy alone 0.067 
[0.011; 0.415]). To conclude, when an engineered oncolytic adenovirus was utilized to modify the tumor 
microenvironment towards what meta-analyses have pointed as predictive markers for checkpoint 
inhibitory therapy, the response to them increased synergistically. Of note, key findings were confirmed 
in fresh patient-derived tumor explants.
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Introduction
The impressive complete responses seen in some patients 
receiving immune checkpoint inhibitors (ICIs), and the 
increasing number of approved indications, are an objective 
sign of their success in terms of cancer therapy. Even though 
this is an ongoing golden era for ICIs, the majority of solid 
tumor patients still do not experience a long-term response. 
Some patients benefit only for a limited time while the majority 
derive no detectable benefit, especially when it comes to com-
mon types of non-melanoma solid tumors. Thus, ICIs have 
definitely been validated as an approach, but since a minority 
of patients benefit from them, there is an unmet clinical need.
An example of such unmet need can be seen in renal cell 
carcinoma (RCC) for which an anti-PD-1, nivolumab, has been 
approved for second-line treatment. In a randomized phase 3 
trial, the confirmed response rate was 21.5% in the ICI arm 
versus 3.9% in the everolimus (an inhibitor of the mammalian 
target of rapamycine) arm. Median overall survival (OS) was 
25.0 and 19.1 months, respectively.1 Another clinical trial 
combined the use of an ICI (atezolizumab, anti-PD-L1) with 
an anti-VEGF (sunitinib) drug, increasing the overall response 
rate (ORR) to 32% (25% for anti-PD-L1 as monotherapy and 
29% for sunitinib as monotherapy).2 RCC is a tumor type 
previously described as “immunogenic” and some patients 
respond to high dose IL-2 treatment,3 but the majority show 
no response to immunotherapies. Clear room for improvement 
exists in most tumor types, since ORR is still low (melanoma 
40%,4 urothelial carcinoma 21,1%,5 non-small-cell lung cancer 
19.4%,6 hepatocellular carcinoma 14.3%,7 among others).
Increasing the frequency of responses to ICIs is now 
a paramount aim for the entire cancer immunotherapy field. 
To understand the differences between patients and to corre-
late those with their clinical outcomes, many retrospective 
analyses have been performed. The most consistent findings 
correlate outcome with the presence of tumor-infiltrating lym-
phocytes (TILs), PD-L1 expression, total mutational burden, 
and the expression of immunostimulatory cytokines including 
interferon gamma (IFNg), tumor necrosis factor alpha (TNFa), 
and interleukin-2 (IL-2) among others.8-14
T-cell trafficking, PD-L1 expression, and cytokine signa-
tures are features that can be addressed by the use of viral 
platforms. The era of using oncolytic viruses (OVs) solely for 
their direct tumor oncolytic ability while ignoring the effect 
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they have on the immune system has morphed into oncolytic 
immunotherapy,15 since human data indicated that the most 
relevant result of viral oncolysis appears to be related to the 
induction of anti-tumor immunity.16 New generation oncolytic 
viruses are designed taking into account their lytic activity, but 
more importantly, highlighting their immune-related features 
such as immunogenic cell death, the release of tumor- 
associated antigens, pathogen-associated molecular patterns 
(PAMPs), damage-associated molecular patterns (DAMPs) 
and upregulation of MHC. Thus, OVs can stimulate both 
innate and adaptive immune systems.17
Besides the intrinsic ability of viruses to interact with the 
immune system, they can be engineered to express cyto-
kines, enzymes, or other proteins to target certain immune 
pathways. In short, many current OVs aim to destroy the 
tumor by engaging the immune system to do it. Oncolytic 
replication is also important, but perhaps chiefly because of 
its immunostimulatory consequences. Ad5/3-E2F-d24- 
hTNFa-IRES-hIL2 (TILT-123) is an engineered oncolytic 
adenovirus with chimeric serotype 5/3 designed specifically 
to be coupled with T-cell-related therapies such as adop-
tive-cell transfer18(such as chimeric antigen receptor [CAR] 
T-cell therapy19) or ICIs.20 To go beyond the inherent 
immunostimulatory activity of the presence of adenovirus 
in tumors, TILT-123 was tailored to enhance the antitumor 
effect of CD8 T cells. After infection with the virus, the 
tumor cell will express virally delivered TNFa and IL-2 
genes before dying. These two cytokines are released into 
the tumor microenvironment to attract T cells toward the 
tumor to sustain their proliferation and activity.21–23 The 
addition of ICIs would keep newly recruited or locally 
generated TILs protected from the inhibitory signals 
exploited by the tumor.
Our main hypothesis is that the use of a genetically modified 
adenovirus armed with TNFa and IL-2 changes the tumor 
circumstances toward those seen in patients with the best 
responses to ICI (“hot tumors,” understood as tumors highly 
infiltrated with antitumor immune cells), and those changes 
might help to increase the response rate to checkpoint block-
ade. To test the abovementioned hypothesis, we used human 
tumor histocultures and an in vivo model allowing us to 
approach the questions from different angles. These allowed 
us to study tumor microenvironment remodeling at the cellu-
lar and cytokine level but also anti-tumor efficacy and OS.
Materials and methods
Human tumor histocultures from urological tumor 
samples
Urological samples were collected from surgically removed 
kidneys and turned into single-cell suspension following the 
previously described methodology.24 In short, tissues were cut 
into fragments of an approximate diameter of 5 mm and then 
incubated overnight in a medium containing various enzymes 
to create a single-cell suspension that was subsequently plated 
into 6-well plates. Single-cell cultures were treated with viruses 
(Ad5/3-E2 F-d24-hTNFa-IRES-hIL2, multiplicity of infection 
100), 20 µg/mL of anti-human PD-L1 (Atezolizumab, Roche, 
Basel, Switzerland), or the both in triplicates. Cytokine produc-
tion and cell viability were assessed after 1, 3, and 7 d.
Histopathology analyses
Hematoxylin and eosin (H&E), and CD8 (clone 4B11, CD8- 
4B11-L-CE-H, Leica Biosystems, Wetzlar, Germany) stainings 
were performed on patient samples and analyzed by a trained 
pathologist. For PD-L1 expression assessment, the PD-L1 
VENTANA (SP142) assay (Roche, Basel, Switzerland) was 
performed by a trained pathologist and scored under routine 
protocols in the clinical set-up. Histopathological analyses 
from murine samples were carried out by a veterinary pathol-
ogist as described previously.25
Cell viability assay
Human tumor histocultures were treated (as described before) 
up to 7 d. Cell viability was assessed with "Cell Titer 96 
AQueous One Solution Cell Proliferation Assa" (G3582, 
Promega, Madison, Wisconsin, USA), following manufacturer 
indications. The viability of mock-treated cells was set to 100%.
In vivo experiments
To study treatment-induced changes in tumors, 2.5 × 105 B16. 
OVA melanoma cells were implanted subcutaneously on 
4–6 week old female C57BL/6JOlaHsd mice (Envigo Labs, 
Huntingdon, UK). Eleven days after engraftment, animals 
were randomized into groups (n = 12-14/group). Then, they 
received systemic treatments of 0.1 mg of anti-PD-L1 (clone 
10 F.9G2, BE0101, BioXCell, Lebanon, New Hampshire, USA) 
and intratumoral injections of 1 × 108 vp (including equal 
amounts of Ad5-CMV-mIL2 and Ad5-CMV-mTNFa viruses, 
non-replicative in mice) on days 0, 1, 3, and 6. PBS was injected 
intratumorally for groups that did not receive virus. On day 7, 
6 animals per group were sacrificed and tumors collected to 
investigate immune-cell phenotyping and cytokine signatures. 
The rest of the animals (n = 6–8/group) continued to a 90-d OS 
study, where the treatments continued once every 3 d, until 
maximum tumor size reached (18 mm) or complete tumor 
regression.
Cell lines and viruses
B16.OVA, a mouse melanoma cell line was cultured under 
recommended conditions.20 The cytokine-armed murine ade-
noviruses’ (Ad5-CMV-mIL2 and Ad5-CMV-mTNFa) con-
struction and production have been described previously23 
and were used in the in vivo experiments. For the human 
tumor histoculture experiments, the oncolytic Ad5/ 
3-E2 F-d24-hTNFa-IRES-hIL2 (known as TILT-123)21 was 
used.
Cytokine analyses
Cell culture medium supernatants coming from tumor histo-
cultures were collected after 1, 3, and 7 d. Sample size for the 
cytokine analyses was restricted on availability of tumor sample 
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(mock; n = 4, aPD-L1; n = 6, virus; n = 3, virus+aPD-L1 (S); 
n = 2, virus+aPD-L1 (PB); n = 0). The cytokine levels (IFNg, 
TNFa, IL-2, IFNb, granzyme B, CXCL10, IL-6, arginase, and 
TGF-b1) on the samples were assessed with a custom 
Legendplex panel (Biolegend, Dedham, Massachusetts, USA) 
and a Free Active/Total TGF-b1 detection kit (740488, 740486, 
and 740487, Biolegend, Dedham, Massachusetts, USA). 
Cytometric Bead Array Mouse Th1/Th2/Th17 Cytokine kit 
(560485, BD, Franklin Lakes, New Jersey, USA) was used to 
study murine tumor samples as described before.20 Both cyto-
kine bead arrays were analyzed with Accuri® (BD, Franklin 
Lakes, New Jersey, USA). The obtained cytokine values were 
normalized to total protein concentration of the sample.
PD-L1/2 expression assays
When studying PD-L1 expression dynamics, B16.OVA cells 
were treated with 1000 U/mL of murine IFNg (315–05, 
Peprotech, Stockholm, Sweden), a known inducer for PD-L1 
expression. Mock control cells were left untreated. After 24 h of 
culture, a fraction of the cells were checked for PD-L1 expres-
sion and the rest were washed twice with PBS and passed to 
duplicate 12-well plates. Part of the cells previously treated with 
IFNg stopped receiving the treatment (“withdrawn” group) and 
the other part continued with the treatment (“IFNg kept” 
group). The plates were analyzed 24 h and 72 h after the plating.
Similarly, the effect of IFNg (1000 U/mL), TNFa (1000 U/mL 
and 10000 U/mL), IL-2 (1000 U/mL and 10000 U/mL), Ad5-luc 
(1 and 100 vp/cell), Ad5-CMV-mIL2 (1 and 100 vp/cell), Ad5- 
CMV-mTNFa (1 and 100 vp/cell), or different combinations of 
those on PD-L1 and PD-L2 expression on B16.OVA cells. These 
expression levels were studied at 24- and 72-h time points.
Flow cytometry
Cell cultures and tumor samples were processed and labeled as 
described elsewhere.20 Anti-CD4-FITC (clone GK1.5, 100406, 
Biolegend, Dedham, Massachusetts, USA), anti-CD3e-PE (clone 
145-2C11, 12-0031-82, eBioscience, San Diego, California, 
USA), anti-CD69-PE-Dazzle (clone H1.2 F3, 104536, 
Biolegend, Dedham, Massachusetts, USA), anti-CD8-PE-Cy5 
(clone 53.6–7, 100710, Biolegend, Dedham, Massachusetts, 
USA), anti-PD-1-PE-Cy-7 (clone 29 F.1A12, 135216, 
Biolegend, Dedham, Massachusetts, USA), anti-CD45-FITC 
(clone 30-F11, 103107, Biolegend, Dedham, Massachusetts, 
USA), anti-PD-L2-PE (clone MIH5, 558091, BD, Franklin 
Lakes, New Jersey, USA), anti-Gr-1-PE-Dazzle (RB6-8C5, 
108452, Biolegend, Dedham, Massachusetts, USA), anti-CD11b- 
PE-Cy5 (M1/70, 101210, Biolegend, Dedham, Massachusetts, 
USA), anti-PD-L1-PE-Cy7 (TY-25, 107214, Biolegend, 
Dedham, Massachusetts, USA) were used for flow cytometric 
analyses under manufacturer’s indications. The analyses were 
performed with SH800Z cytometer (SONY, Minato, Japan).
Statistical analyses
Tumor growth evolution was studied by a mixed-model ana-
lysis of log-transformed tumor volumes with SPSS Statistics 25 
(IBM, Armonk, New York, USA). GraphPad (San Diego, 
California, USA) software was used to present the data, to 
analyze OS (Kaplan–Meier, Log-rank Mantel–Cox test), 
Hazard Ratios (HRs), and 95% confidence intervals (CIs). In 
addition, GraphPad was used to evaluate the differences 
between groups in cytometry or cytokine analyses (unpaired 
t-test with Welch’s correction), correlation analyses between 
variables (Pearson’s r), over-time evolution of variables (two- 
way ANOVA), and linear regression. Synergy was calculated 
using the fractional tumor volume (FTV) method. P values < 
.05 were considered statistically significant. Data is available 
upon reasonable request.
Ethics approval and consent to participate
Central Hospital Operative Ethics Committee approved the 
studies (HUS/850/2017) performed on patients’ material and 
written informed consent was given by the patients. 
Experimental protocols for animal studies were reviewed and 
approved by the ethical committee from the National Animal 
Experiment Board of the Regional State Administrative Agency 
of Southern Finland, and all the procedures were carried out in 
accordance with the recommendations in the Act on the 
Protection of Animals Used for Scientific or Educational 
Purpose (497/2013) and Government Decree on the 
Protection of Animals Used for Scientific or Educational 
Purposes (564/2013) as well as the European Directive 2010/ 
63/EU.
Results
Oncolytic adenovirus-mediated tumor cell lysis in 
patient-derived urological tumor histocultures
To understand how oncolytic virotherapy can enable responses 
to checkpoint inhibitors in solid tumors, three surgically 
removed tissues were studied. The tumor types (urothelial 
carcinoma: sample 1. Clear cell renal cell carcinoma: samples 
2 and 3) are currently approved26 for anti-PD-L1 treatment or 
there are Phase III clinical studies showing evidence of benefit 
for the therapy27. These tumors were pathological grade 3 
(sample 2) or 4 (samples 1 and 3) as evaluated from the 
hematoxylin and eosin staining (Figure 1a). Because one of 
the primary effects of the virally delivered cargo affects 
CD8 + T cells, their presence was also assessed (Figure 1b), 
showing two samples with an immune-excluded (“cold”) phe-
notype (Samples 1 and 2) and one with an immune-inflamed 
(“hot”) phenotype (sample 3). In addition, of relevance for 
anti-PD-L1 targeting, an assay to determine PD-L1 positivity 
was performed. This showed PD-L1 expression below 5% in 
immune cells in all samples, making them negative according 
to the test guidelines (Figure 1c).
After sample processing, a viability assay was performed to 
measure how the treatments affected the survival of tumor 
histocultures (Figure 1d). By day 7, a statistically significant 
decrease in tumor viability was achieved with virotherapy in all 
three samples when compared with mock or anti-PD-L1 
monotherapy (p < .01). At that time, the viability of the virally 
treated groups dropped 62% (95%CI = [54.19; 69.89]) com-
pared with mock and 56% (95%CI = [38.49; 73.39]) when 
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compared with anti-PD-L1-treated samples. Already on day 1, 
there were significant reductions on cell viability in two of the 
samples, when virus and anti-PD-L1 were given together.
Oncolytic virotherapy triggers a broad 
immunostimulatory response in human urological tumor 
histocultures
We also studied the histocultures for the impact of the treat-
ments on cytokine levels (Figure 2). Because of the heterogeneity 
typically seen in actual patient tumors, cytokine levels between 
samples varied. Nevertheless, groups receiving virotherapy dis-
played a clear trend for increased expression of immunostimu-
latory cytokines (IFNg, TNFa, IL-2, granzyme B, and CXCL10) 
(Figure 2a-f, Supp. Figure 2). Regarding IFNg, increased produc-
tion was achieved when Ad5/3-E2 F-d24-hTNFa-IRES-hIL2 was 
administered together with anti-PD-L1 in comparison with 
“Mock” (p = .0182) and “anti-PD-L1” alone groups 
(p = .0181). The “Virus” alone group had a similar trend 
(p = .068). TNFa and IL-2 production were also increased in 
Figure 1. Urological cancer patient-derived samples respond to oncolytic virotherapy despite phenotypical differences. Patient sample 1 is urothelial carcinoma, patient 
samples 2 and 3 are Clear cell renal cell carcinoma. (a) Hematoxylin and Eosin staining performed on the paraffin-embedded samples. (b) CD8 immunohistochemistry. 
(c) PD-L1 immunohistochemistry. (d) MTS viability assay after ex vivo treatment of the histocultures. Statistical significances are shown for  day 7 calculated by unpaired 
t-test with Welch’s correction (**p < .01; ***p < .001). Mean and standard error of the mean (SEM) are shown.
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virally treated groups and the differences were significant when 
samples were analyzed individually (Supp. Figure 2b-c). IFNb 
production, on the other hand, was not as clearly affected as the 
other immunostimulatory cytokines, except for a peak in pro-
duction on day 3 with the double treatment.
Granzyme B and CXCL10 had higher expression values in 
virally treated groups. The expression of these two proteins 
correlated with IFNg expression (IFNg/Granzyme B: r = 0.629 
[0.376; 0.792], p < .001. IFNg/CXCL10: r = 0.494 [0.198; 0.708], 
p = .002). CXCL10 expression was significantly increased in 
“Virus” group when compared with “Mock” (p = .003) and 
with “anti-PD-L1” (p = .002). Treatment with aPD-L1 alone 
did not affect the expression of immunostimulatory markers 
compared with “Mock” group.
Statistically significant reduction of IL-6 was achieved by 
“anti-PD-L1” group and “Virus + anti-PD-L1” when com-
pared with “Mock” or “Virus” in two out of three samples 
(Supp. Figure 2g). Regarding immunosuppressive mediators 
(TGF-b, and arginase), effects of treatments are not as clear 
as for the stimulatory ones. For TGF-b (Supp. Figure 2h) 
significant decreases were achieved in all samples for the 
“Virus + anti-PD-L1” group, while for “anti-PD-L1” group 
this was seen only in one sample. Arginase was included in 
the panel, despite the fact not being a cytokine but an 
enzyme affecting immune activity. For this enzyme, one 
sample displayed reduced expression in the “anti-PD-L1” 
group and “Virus + anti-PD-L1” when compared with 
“Mock” or “Virus” (Supp. Figure 2i).
Treatment-induced immunostimulatory cytokine 
production relates to the reduction of viability in solid 
tumor samples
To compare the differential expression of markers in tumor 
histocultures on day 7, average fold change compared with 
“Mock” was plotted side-by-side (Figure 3a,b). Among the six 
stimulatory markers analyzed, the increase in TNFa and IL-2 
expression is likely related, at least partially, to viral expression 
of the transgenes and cannot be distinguished from the endogen-
ous production. Of note, there was more than a 1000-fold increase 
in TNFa expression and around a 100-fold increase for IL-2. 
Regarding IFNg, virally treated groups displayed over a 100-fold 
increase compared with mock conditions. Interestingly, the addi-
tion of anti-PD-L1 to virus treatment results in 10 times higher 
expression when compared to virus alone (1000 times higher than 
in “Mock”). Additionally, virus treatments induced an average of 
25-fold increase in CXCL10 levels.
The treatments had a less drastic effect on the expression 
levels of TGF-b, and arginase (Figure 3b). Anti-PD-L1 therapy 
seemed to reduce the amount of TGF-b, while arginase expres-
sion was reduced only when both the virus and the checkpoint 
inhibitor were given together. To compare the presence of the 
measured immune-suppressors and immune-stimulators pre-
sent at the tumor, average values of TGF-b and arginase were 
plotted against average values of IFNg, IFNb, granzyme B, and 
CXCL10 (Figure 3c), to have an overall view on the two types 
of signals for each group. The use of both treatments together 
Figure 2. Responses to virotherapy and checkpoint inhibitor treatments at the cytokine level across 7 d of treatment. Expression values from three individual patient- 
derived tumor histocultures were plotted together. (a) IFNg. (b) TNFa. (c) IL-2. (d) IFNb. (e) Granzyme B.  (f) CXCL10. (g) IL-6. (h) TGFb. (i) Arginase. Statistical significances 
calculated by two-way ANOVA. (*p < .05; **p < .01). Mean and standard error of the mean (SEM) are shown.
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induced a decrease in immune suppression, delivered by the 
checkpoint inhibitor, and immunostimulation via virotherapy. 
An inversely proportional correlation was seen between the 
production of immunostimulatory cytokines and the tumor 
histoculture cell viability (r = −0.716 [−0.914; −0.241], 
p = .009)(Figure 3d). No correlation was found between cell 
viability and immunosuppressive cytokines.
TNFa and IL-2 expressing adenoviruses enable anti-PD-L1 
therapy in vivorendering 100% complete response rate
Next, we aimed to assess if immune-stimulation triggered by 
the virus and reduced suppression achieved by anti-PD-L1 was 
reproducible in vivo. In addition, we wanted to study the 
impact of tumor immune remodeling in terms of anti-tumor 
efficacy (Figure 4a). To understand the interaction between the 
treatments, two groups were treated with viruses and check-
point inhibitors but with different administration regimens; 
while one group received both treatments simultaneously (S) 
the other received the virus treatment, in a “prime and boost” 
manner (PB). In the prime and boost group, the virus is given 
without anti-PD-L1 for two rounds and then anti-PD-L1 is 
included in the treatment.
The two groups that received viruses and anti-PD-L1 together 
displayed better results in terms of survival than the other groups 
(Figure 4b). Particularly, when the viruses (intratumoral) were 
administered simultaneously with anti-PD-L1 (intravenous), 
100% complete response rate was achieved. The “Virus + aPD- 
L1 (s)” group had significantly longer survival than any other 
group (p < .001 against “Mock,” p = .007 against “aPD-L1,” 
p = .005 against “Virus” and p = .025 against “Virus + aPD-L1 
(PB)”). The hazard ratio of the “Virus + aPD-L1 (s)” strategy was 
superior over any other group studied (HR = 0.033 [0.006; 0.181] 
against “Mock,” HR = 0.057 [0.007; 0.451] against “aPD-L1,” 
HR = 0.067 [0.011; 0.415] against “Virus” and HR = 0.104 [0.014; 
0.752] against “Virus + aPD-L1 (PB)”).
The “prime and boost” approach resulted in significantly 
longer OS (p < .001) and lower HR (0.059 [0.012; 0.290]) over 
mock. Virotherapy or checkpoint inhibitor monotherapy 
resulted in circa 33% CR. OS with virotherapy alone was 
statistically improved over mock (p = .016), with a lower HR 
(0.180 [0.044; 0.727]). Individual tumor volume graphs were 
also plotted (Figure 4c) and synergistic effects were seen fol-
lowing dual therapy (Supp. Figure 3) as early as day 5. At day 
90 after the treatments started, some of the animals that had 
undergone a complete response had a scar tissue in the peri-
tumoral area. After the sacrifice of the animals, scars were 
collected and analyzed by a pathologist (Supp. Figure 4), who 
reported the presence of melanophages, plasma cells, and lym-
phocytes, but no malignant cells.
Virotherapy increases the amount of active CD8T cells 
intratumorally in vivo
To assess the early immunological impact of the treatments, six 
animals per group were randomly selected, sacrificed, and 
Figure 3. Analyses of grouped cytokine responses to virotherapy and checkpoint inhibitor treatments on day 7. Expression values from three different patient-derived 
tumor histocultures were plotted together. (a) Fold change in immunostimulatory cytokines. (b) Fold change in immunosuppressive effectors. (c) Overall suppression 
(including TGF-b and arginase) vs overall stimulation (including IFNg, IFNb, granzyme B, and CXCL10). (d) Pearson’s r  correlation between immunostimulatory cytokine 
expression and tumor histoculture viability.
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tumors collected on day 7. Virotherapy increased the propor-
tion of CD8 + T cell trafficking to the tumor (Figure 5a). 
Statistical significances were achieved for the “Virus” group 
(p = .011) and in the “virus + aPD-L1 (PB)” (p = .003) when 
compared with “Mock,” which had almost no infiltration of 
CD8+ cells. The other virally treated group, “virus + aPD-L1 
(s),” also had a sub-significant increase in CD8+ T cells 
(p = .093), but the highest mean levels among all the groups. 
Regarding the total CD8 T-cell population present in tumors, 
there were more activated cells (based on CD69 expression) 
when the animals were treated with virotherapy (p < .05 for all 
the virally treated groups) (Figure 5b).
Upon measuring the proportion of active CD8 T cells out of 
total cells, the average values in virally treated groups were up 
to 100 times higher (virus + aPD-L1 (s)) when compared with 
“Mock” values (Figure 5c). The percentage of PD-1 positive 
cells among tumor-infiltrating CD8 T cells was nearly 100% for 
all groups (Figure 5d). When PD-1 expression intensity was 
addressed, significant differences were observed in the groups 
receiving viral vectors (Figure 5e). In fact, PD-1 expression 
intensities correlated with the percentage of active T CD8 
cells (r = 0.927 [0.849; 0.9655], p < .0001) (Supp. Figure 5a).
The CD8/CD4 ratio increased in treated groups (Figure 5f). 
There is also a trend toward an increase in CD4+ cells in the 
groups treated with both virus and ICI (Figure 5g), but in a less 
steep manner than CD8+cells. Regarding the overall trafficking 
of leukocytes (defined here as CD45+ cells), tumors treated 
with viruses displayed a significant increase (Figure 5h).
In the context of anti-PD-L1 therapy, it is especially relevant 
to understand the expression of tumor PD-L1 and PD-L2. For 
that reason, it was studied if any of the cytokines encoded by 
the viruses, the viruses themselves, or their combination was 
able to upregulate PD-L1 (Supp. Figure 6a) or PD-L2 (Supp. 
Figure 6b). Unlike IFNg, the cytokine-producing virus or the 
components separately did not upregulate PD-L1 or PD-L2. 
Interestingly, induction achieved with IFNg was reversible as 
the levels returned to the baseline after 72 h of culturing with-
out IFNg (Supp. Figure 6c-e). In accordance, the groups with 
a higher presence of active CD8 T cells and higher IFNg 
production (see below) displayed a higher percentage of PD- 
L1+ tumor cells (Figure 5i) and the highest PD-L1 intensity 
(Figure 5j).
Alteration of PD-L1 expression by IFNg did not occur in the 
leukocyte fraction. The only group with a statistically signifi-
cant increase in the percentage of PD-L1+ cells (Figure 5k) and 
PD-L1 intensity (Figure 5l) was the one treated with anti-PD- 
L1 monotherapy.
PD-L2 expression was also studied (Supp. Fig 7a-d). In this 
case, virus monotherapy induced a significant increase in the 
percentage of positive cells when compared with every other 
Figure 4. In vivo testing of virotherapy to enable checkpoint inhibitory therapy. (a) Experimental design: 66 animals with B16.OVA tumors started treatments on  day 0. 
Thirty of them were sacrificed on  day 7 post-treatment (gray-dashed line) and tumors collected while the rest were kept alive for a  survival experiment, with more 
rounds of treatments until tumors regressed completely or death (S: simultaneous administration of virus and aPD-L1, PB: prime and boost). (b) Overall survival (Kaplan– 
Meier, Log-rank Mantel–Cox test). (c-g) Individual tumor growth lines. (*p < .05; **p < .01, ***p < .001).
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group in both CD45- and CD45+ populations (“tumor” and 
“leukocyte,” respectively). It is noticeable that both monothera-
pies increased PD-L2 signals, but that increase did not occur 
when therapies were administered together. PD-L2 effects are 
of unknown significance at this point, since the role of this 
molecule in immunotherapy is unclear in general.
Myeloid-derived suppressor-like cells (MDSCs) constitute 
another relevant cell population due to their ability to disable 
immune activity. For that reason, they were studied in terms of 
suppressive ligands (Supp. Fig 7e-j). Their inherent suppres-
sivity was observed as all of them expressed PD-L1 and PD-L2, 
the levels being more intense in the group treated with virus as 
monotherapy.
Oncolytic virotherapy triggers a broad 
immunostimulatory cytokine response in vivo
Similarly, as done with urological human tumor histocultures, 
we proceeded to study the differential expression of immune- 
stimulatory and immune-suppressive cytokines in melanoma 
tumors collected 7 d after treatments started. A trend for 
increased IFNg production was observed for the “virus+aPD- 
L1 (S)” group, which was less marked for groups treated with 
monotherapies (Figure 6a). The IFNg production correlated 
with the presence of CD8 T cells in the tumors (r = 0.720 
[0.330; 0.900]) (Suppl Figure 5b).
Regarding TNF and IL-2, virally treated animals expressed 
high levels (Figure 6b-c), most likely deriving from the viruses 
at least in part. Suppressive cytokines, such as IL-4 and IL-10, 
seemed to be higher in “Mock” conditions, while both check-
point inhibitors and viruses reduced their expression (Figure 
6d-f). When immunosuppressive and immunostimulatory 
cytokines were plotted together, we did not observe remarkable 
differences between the two groups receiving virotherapy, but 
there was a trend toward lower immunosuppression and 
increased immunostimulation when comparing those groups 
with “Mock” and “anti-PD-L1” (Figure 6g).
Another correlation was found between the presence of 
active (CD69+) CD8 T cells and IFNg in the tumor microen-
vironment (r = 0.782[0.451; 0.924]) (Figure 6h). The groups 
with higher IFNg also displayed increased PD-L1 expression 
on tumor cells (Figure 5i,j).
Discussion
In this study, we show how a viral platform coding for TNFa 
and IL-2 has a considerable impact on the immune tumor 
microenvironment, which led to higher responses in the con-
text of anti-PD-L1 checkpoint inhibition. Similar results were 
observed both in human urological clinical sample histocul-
tures (renal cell cancer and urothelial cancer) and in vivo, 
resulting in improved tumor growth control and survival. It 
is noteworthy that both monotherapies had a positive effect. 
When they were used together, synergistic antitumor control 
was clear in the context of tumor control when studied in 
immunocompetent models, and beneficial outcomes were 
observed when analyzing immune mediators. Importantly, 
checkpoint inhibition prevented the switching-off of crucial 
Figure 5. In vivo responses to virotherapy and checkpoint inhibitor treatments on day 7 analyzed by flow cytometry. (a) %CD8 + T cells out of total cells. (b) %CD69+ out 
of CD8 + T cells. (c) %CD69+ CD8 + T cells out of total cells. (d) %PD-1+ out of CD8 T cells. (e) PD-1 intensity on CD8 + T cells. (f) CD8/CD4 ratio. (g) %CD4+ cells out of 
total cells. (h) %CD45+ cells out of total cells. (i) %PD-L1+ cells out of CD45- cells. (j) PD-L1 intensity on CD45- cells. (k) %PD-L1+ cells out of CD45+ cells. (l) PD-L1 
intensity on CD45+ cells. Mean and standard error of the mean (SEM) are shown. Differences between groups calculated by (*p < .05; **p < .01, ***p < .001).
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virus-mediated anti-tumor immune responses. It was only 
when both aspects were taken into account (activation and 
prevention of de-activation) that the immune system was able 
to completely eradicate tumors.
In patients, complete responses are quite rare, partial 
responses are more common, but even taken together, ORR 
with ICIs are between 10–40% following monotherapy in most 
solid tumor types. However, it has been noted that TIL 
presence8,9 and upregulated inflammatory cytokine signature11- 
13 are among the strongest predictive factors. In this regard, it is 
potentially important that the studied viral platform was able to 
make “cold” tumors “hot,” to enable effective ICI therapy, for an 
increased response rate and survival. In animal studies, we 
observed how the presence of TILs increased after virus treat-
ment, and rose further when combined with a checkpoint inhi-
bitor, showing again the rationale for their combination. This 
finding is especially relevant in the model used, where the pre-
sence of CD8 T cells is near zero in Mock conditions. The effect 
of the approach in inducing CD8 trafficking to solid tumors was 
later validated in a different in vivo model (Supp. Figure 8). The 
ability of the TNFa and IL2 coding adenovirus to increase TIL 
trafficking towards the tumor has been previously described by 
immunohistochemistry19 and SPECT/CT.23 In tumor histocul-
tures, groups receiving virotherapy also showed higher 
expression of CXCL10, a chemokine able to promote TIL 
trafficking.28 With regard to inflammatory cytokine signatures, 
extensive upregulation was seen both ex vivo and in vivo.
Other relevant predictive factors are total mutational bur-
den and PD-L1 expression. The mutational burden relates to 
the probability of immune responses.29,30 In this regard, vir-
otherapy probably does not increase or reduce the mutational 
burden actively, but it has been shown that oncolysis is 
a mechanism for releasing neoantigens, enhancing their avail-
ability to antigen-presenting cells.31,32 PD-L1 expression has 
been used as an indication-defining marker for some tumor 
types such as non-small-cell lung cancer.33 However, its base-
line expression is not a fully reliable marker.10,12,34 The fact 
that PD-L1 can be expressed both on tumor and immune cells 
lowers its predictive value. Additionally, PD-L1 expression 
could imply different things if it is present as a response to 
IFNg or because of epigenetic dysregulation indicating 
immunosuppression.35
In our studies, we observed that PD-L1 was upregulated in 
tumor cells in those groups with higher expression of IFNg. 
This observation raised the question whether PD-L1 upregula-
tion could be explained by direct IFNg exposure or by some 
other component of the treatment. To address this issue, we 
exposed cancer cells to treatment components (backbone 
Figure 6. Responses to virotherapy and checkpoint inhibitor treatments at the cytokine level from in vivo experiment on day 7. (a) IFNg production. (b) TNF production. 
(c) IL-2 production. (d) IL-4 production. (e) IL-6 production. (f) IL-10 production. (g) Overall suppression (including IL-4 and IL-10) vs overall stimulation (including IFNg, 
TNF, and IL-2). (h) Correlation analysis between IFNg production and active T  cells.
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viruses and recombinant TNFa/IL-2, altogether and separately) 
and IFNg. We observed that IFNg stimulus directly produced 
PD-L1 upregulation on tumor cells but the same did not occur 
with the rest of the elements involved in the treatments.
In the previous work,20 we addressed the issue of the 
sequencing administration of virus and anti-PD-1 ICI. We 
showed that delaying the administration of anti-PD-1 was 
beneficial for anti-tumor effects, and provided some specula-
tion on the mechanism of the prime-and-boost. In contrast, 
our results reported here suggest that for PD-L1 blockade 
simultaneous administration is more effective. Zamarin, 
D et al.36 arrived at similar conclusions when using 
Newcastle Disease Virus in combination with anti-PD-L1. 
A possible mechanistic explanation is that the first wave of PD- 
L1 upregulation in the tumor is related to a virotherapy- 
induced innate cytokine-mediated response, while after 
4–5 d, when PD-1-positive lymphocytes get to the tumor, the 
adaptive responses trigger another wave of PD-L1 upregula-
tion. This hypothesis suggests that PD-1 blockade would be 
needed only after 4–5 d, while PD-L1 blockade is useful from 
the moment the virus is delivered into the tumor. Another 
plausible explanation on the difference between antibodies 
could be that the anti-PD-L1 used here is able to trigger anti-
body-dependent cellular cytotoxicity while the anti-PD-1 used 
previously is not as suggested by Dahan, R. et al.37 It is of 
importance to note that not all ICIs are alike when it comes to 
combination use with oncolytic viruses. Preclinical studies can 
be useful in providing a rationale for clinical translation.
Combination immunotherapy is being widely explored and 
the use of OVs with ICIs has produced promising results in early 
clinical trials.38,39 One of the most encouraging approaches 
features the combination of talimogene laherparepvec (herpes 
virus expressing granulocyte-monocyte colony-stimulating fac-
tor (GM-CSF)) with pembrolizumab (anti-PD-1).40 This study 
reported an increase in response rate (when compared with 
historical ICI-treated cohorts) without any major increase in 
toxicity. A phase 3 trial with this approach is ongoing 
(NCT02263508). It also sets as a promising precedent for the 
combination of these two immunotherapies.
Unlike talimogene laherparepvec, which targets antigen- 
presenting cells, the virus used in this work (Ad5/3-E2F-d24- 
hTNFa-IRES-hIL2 (TILT-123)) was designed in a data-driven 
manner to enable T cells and T-cell therapies including 
ICI.21,22 TNFa, and IL-2 have a direct effect on effector 
T cells, while GM-CSF has only indirect effects. This may be 
a critical advantage in the context of T-cell therapies and ICI. 
In a complementary setting, we compared the virus coding for 
TNFa and IL-2 to the unarmed version, showing the critical 
importance of the transgenes in reshaping the immune 
microenvironment.24 At the preclinical level, the use of vir-
otherapy together with ICI has been studied by others39 but, 
achieving 100% OS and 100% tumor control rate in this model 
is an infrequent achievement. Another relevant feature regard-
ing the experimental design used in the in vivo part of this 
study is that we allowed immunosuppression to develop by 
allowing tumors to grow longer before initiating therapy, as 
compared with other studies in the same model.36,41
Nevertheless, our study has some limitations. First, there are 
no optimal models to test the effect of both treatments. Human 
ex vivo tumor histocultures are an acceptable way to study 
tumor oncolysis and the local impact of the therapies, but the 
entire immune system is not present. Thus, cell trafficking and 
generation of adaptive responses are not possible. Regarding 
animal models, murine cells are not susceptible to adenoviral 
replication. Thus, even if the transgenes are expressed and the 
immune activation is achieved, late stages of the viral cycle do 
not occur, and there is practically no production of new viral 
particles.42 Another model sometimes considered is the Syrian 
hamster (Mesocricetus auratus), as it supports human adeno-
virus replication and oncolysis.43 Unfortunately, there are no 
checkpoint inhibitory antibodies available to study the combi-
nation with the virus.
In conclusion, we have described how an adenoviral plat-
form coding for TNFa and IL-2 can be used to increase 
responses to PD-L1. The mechanism relates to the broad upre-
gulation of stimulatory cytokines (IFNg, IFNb, granzyme B, 
and CXCL10 besides the virally produced TNFa and IL-2) and 
the attraction of active CD8 T cells and other leukocytes to the 
tumor. These changes in the tumor make them resemble 
immunologically “hot” tumors, which often respond to ICIs. 
Understanding what makes patients respond and extending 
this knowledge to other patients will expand the utility of 
tumor immunotherapy to larger patient populations. The 
data provided here set the stage for clinical translation of 
TILT-123 with anti-PD-L1.
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